drugset
drugset / Trial / NCT07444619

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

NCT07444619 ↗

Phase 1 Recruiting 18 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.

Timeline

Start
2026-06-09
Primary completion
2031-12-31
Completion
2033-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 100 mg/m2 Oral
Subject Pazopanib Small molecule 200 mg Oral
Subject Pazopanib Small molecule 200 mg/m2 Oral
Subject Pazopanib Small molecule 300 mg/m2 Oral
Subject Pazopanib Small molecule 400 mg Oral
Subject Pazopanib Small molecule 400 mg/m2 Oral
Subject Pazopanib Small molecule 600 mg Oral
Subject Pazopanib Small molecule 800 mg Oral
Background Ipilimumab Monoclonal antibody 1 mg/kg Intravenous
Background Nivolumab Monoclonal antibody 3 mg/kg Intravenous
Background Trabectedin Small molecule 1.2 mg/m2 Intravenous

Indications

soft tissue sarcoma